GC Green Cross Develops Precision Detection Technology for Thrombus Impurities in Immunoglobulin
Published in an SCIE-Level Journal
GC Green Cross announced on April 6 that it has developed an analytical method capable of precisely verifying the removal of impurities that can cause blood clots during the production process of intravenous immunoglobulin (IVIG). The results of this study were published in the latest issue of the SCIE-level journal, Journal of Microbiology and Biotechnology.
The core of this research lies in the accurate detection of trace amounts of 'FXI (Factor XI·Coagulation Factor XI)' that may remain in the product. FXI is a protein involved in the blood clotting process. If it exists above a certain level in immunoglobulin, it can be converted to FXIa (activated FXI) inside the body, potentially causing thromboembolism by forming blood clots in blood vessels. The U.S. Food and Drug Administration (FDA) and other global regulatory agencies recommend strict monitoring of FXI and FXIa content.
Existing analysis methods have technical limitations in terms of accuracy, as the high concentration of IgG, the main component of immunoglobulin, interferes with analytical signals. This interference can cause false positives, resulting in impurities being measured as higher than they actually are, or can lead to the omission of trace impurities.
GC Green Cross designed an improved analysis method by applying an IgG blocker to fundamentally eliminate these interfering factors. This approach selectively inhibits non-specific reactions, allowing for the accurate detection of only FXI, which is the cause of blood clots. The company explained that it has validated this analytical method according to International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, and has established a proprietary monitoring system capable of continuously tracking impurities throughout the entire process, from raw materials to finished products.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Jaeuk Jung, Head of R&D at GC Green Cross, stated, "With the establishment of this analytical method, we have enhanced our quality control capabilities for immunoglobulins," and added, "Based on this precision analytical technology, we will continue to supply high-quality plasma fractionation products to the global market."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.